Eur-1066-A
Chronic Pancreatitis
Forest LaboratoriesPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Chronic Pancreatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Johns Hopkins University | Phase 3 | BB |
Pancrelipase Changhai Hospital | Phase 4 | BB |
Triamcinalone Centre hospitalier de l'Université de Montréal (CHUM) | Phase 3 | BB |
Pregabalin Asian Institute of Gastroenterology, India | Phase 2/3 | B |
Pioglitazone University of Michigan | Phase 2 | B |
View all 22 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →